124 related articles for article (PubMed ID: 29227568)
21. Efficacy of xanthine oxidase inhibitor for chronic kidney disease patients with hyperuricemia.
Matsuo H; Ishikawa E; Machida H; Mizutani Y; Tanoue A; Ohnishi T; Murata T; Okamoto S; Ogura T; Nishimura Y; Ito H; Yasutomi M; Katayama K; Nomura S; Ito M
Clin Exp Nephrol; 2020 Apr; 24(4):307-313. PubMed ID: 31845065
[TBL] [Abstract][Full Text] [Related]
22. Inhibitory effects of xanthine oxidase inhibitor, topiroxostat, on development of neuropathy in db/db mice.
Takahashi K; Mizukami H; Osonoi S; Ogasawara S; Hara Y; Kudoh K; Takeuchi Y; Sasaki T; Daimon M; Yagihashi S
Neurobiol Dis; 2021 Jul; 155():105392. PubMed ID: 34000416
[TBL] [Abstract][Full Text] [Related]
23. Effects of Febuxostat on Oxidative Stress.
Fukui T; Maruyama M; Yamauchi K; Yoshitaka S; Yasuda T; Abe Y
Clin Ther; 2015 Jul; 37(7):1396-401. PubMed ID: 25913922
[TBL] [Abstract][Full Text] [Related]
24. The effect for hyperuricemia inpatient of uric acid overproduction type or in combination with topiroxostat on the pharmacokinetics, pharmacodynamics and safety of dotinurad, a selective urate reabsorption inhibitor.
Okui D; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):92-102. PubMed ID: 31734820
[TBL] [Abstract][Full Text] [Related]
25. Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia.
Kario K; Nishizawa M; Kiuchi M; Kiyosue A; Tomita F; Ohtani H; Abe Y; Kuga H; Miyazaki S; Kasai T; Hongou M; Yasu T; Kuramochi J; Fukumoto Y; Hoshide S; Hisatome I
J Clin Hypertens (Greenwich); 2021 Feb; 23(2):334-344. PubMed ID: 33400348
[TBL] [Abstract][Full Text] [Related]
26. Protective Effects of Topiroxostat on an Ischemia-Reperfusion Model of Rat Hearts.
Tanno S; Yamamoto K; Kurata Y; Adachi M; Inoue Y; Otani N; Mishima M; Yamamoto Y; Kuwabara M; Ogino K; Miake J; Ninomiya H; Shirayoshi Y; Okada F; Yamamoto K; Hisatome I
Circ J; 2018 Mar; 82(4):1101-1111. PubMed ID: 29491325
[TBL] [Abstract][Full Text] [Related]
27. A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients.
Ohya M; Shigematsu T
Clin Exp Nephrol; 2014 Dec; 18(6):835-6. PubMed ID: 24871070
[No Abstract] [Full Text] [Related]
28. Uricosuric agents decrease the plasma urate level in rats by concomitant treatment with topiroxostat, a novel xanthine oxidoreductase inhibitor.
Taniguchi T; Ashizawa N; Matsumoto K; Iwanaga T; Saitoh K
J Pharm Pharmacol; 2016 Jan; 68(1):76-83. PubMed ID: 26589240
[TBL] [Abstract][Full Text] [Related]
29. [Inhibitors of xanthine oxidoreductase].
Okamoto K
Nihon Rinsho; 2008 Apr; 66(4):748-53. PubMed ID: 18409526
[TBL] [Abstract][Full Text] [Related]
30. Randomized control trial for the assessment of the anti-albuminuric effects of topiroxostat in hyperuricemic patients with diabetic nephropathy (the ETUDE study).
Kato S; Ando M; Mizukoshi T; Nagata T; Katsuno T; Kosugi T; Tsuboi N; Maruyama S
Nagoya J Med Sci; 2016 May; 78(2):135-42. PubMed ID: 27303100
[TBL] [Abstract][Full Text] [Related]
31. Effect of switching xanthine oxidoreductase inhibitor from febuxostat to topiroxostat on urinary protein excretion.
Terawaki H; Hoshi H; Kazama JJ
Clin Exp Nephrol; 2017 Apr; 21(2):356-357. PubMed ID: 28247173
[No Abstract] [Full Text] [Related]
32. Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1
Ohata K; Kamijo-Ikemori A; Sugaya T; Hibi C; Nakamura T; Murase T; Oikawa T; Hoshino S; Katayama K; Asano J; Kimura K; Shibagaki Y
Eur J Pharmacol; 2017 Nov; 815():88-97. PubMed ID: 28888756
[TBL] [Abstract][Full Text] [Related]
33. Renoprotective effects of topiroxostat for Hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): A prospective, randomized, multicentre clinical trial.
Mizukoshi T; Kato S; Ando M; Sobajima H; Ohashi N; Naruse T; Saka Y; Shimizu H; Nagata T; Maruyama S
Nephrology (Carlton); 2018 Nov; 23(11):1023-1030. PubMed ID: 28990729
[TBL] [Abstract][Full Text] [Related]
34. Febuxostat for treating allopurinol-resistant hyperuricemia in patients with chronic kidney disease.
Sakai Y; Otsuka T; Ohno D; Murasawa T; Sato N; Tsuruoka S
Ren Fail; 2014 Mar; 36(2):225-31. PubMed ID: 24152124
[TBL] [Abstract][Full Text] [Related]
35. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
Nakamura T; Murase T; Nampei M; Morimoto N; Ashizawa N; Iwanaga T; Sakamoto R
Eur J Pharmacol; 2016 Jun; 780():224-31. PubMed ID: 27038523
[TBL] [Abstract][Full Text] [Related]
36. Potency on lowering serum uric acid in gout patients: a pooled analysis of registrative studies comparing febuxostat vs. allopurinol.
Cutolo M; Cimmino MA; Perez-Ruiz F
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4186-4195. PubMed ID: 29028079
[TBL] [Abstract][Full Text] [Related]
37. Effect of uric acid-lowering therapy on blood pressure: systematic review and meta-analysis.
Qu LH; Jiang H; Chen JH
Ann Med; 2017 Mar; 49(2):142-156. PubMed ID: 27689859
[TBL] [Abstract][Full Text] [Related]
38. Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study.
Gunawardhana L; McLean L; Punzi HA; Hunt B; Palmer RN; Whelton A; Feig DI
J Am Heart Assoc; 2017 Nov; 6(11):. PubMed ID: 29102979
[TBL] [Abstract][Full Text] [Related]
39. Is rasburicase an effective alternative to allopurinol for management of hyperuricemia in renal failure patients? A double blind-randomized study.
De Angelis S; Noce A; Di Renzo L; Cianci R; Naticchia A; Giarrizzo GF; Giordano F; Tozzo C; Splendiani G; De Lorenzo A
Eur Rev Med Pharmacol Sci; 2007; 11(3):179-84. PubMed ID: 17970234
[TBL] [Abstract][Full Text] [Related]
40. Influence of xanthine oxidoreductase inhibitor, topiroxostat, on body weight of diabetic obese mice.
Nakamura T; Nampei M; Murase T; Satoh E; Akari S; Katoh N; Mizukami H
Nutr Diabetes; 2021 Apr; 11(1):12. PubMed ID: 33850106
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
